MDXH Stock Overview
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
MDxHealth SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.02 |
52 Week High | €6.90 |
52 Week Low | €1.98 |
Beta | 0.79 |
1 Month Change | 5.19% |
3 Month Change | 11.44% |
1 Year Change | -52.29% |
3 Year Change | -66.07% |
5 Year Change | -81.31% |
Change since IPO | -96.03% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge
Oct 05MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?
Aug 29MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt
Apr 21Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?
May 05Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money
Nov 08MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?
Mar 23MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years
Jan 29Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?
Nov 27Shareholder Returns
MDXH | BE Biotechs | BE Market | |
---|---|---|---|
7D | -5.6% | 4.3% | 3.5% |
1Y | -52.3% | -2.7% | -2.4% |
Return vs Industry: MDXH underperformed the Belgian Biotechs industry which returned -7.7% over the past year.
Return vs Market: MDXH underperformed the Belgian Market which returned 1.2% over the past year.
Price Volatility
MDXH volatility | |
---|---|
MDXH Average Weekly Movement | 10.9% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 3.6% |
10% most volatile stocks in BE Market | 7.0% |
10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: MDXH's share price has been volatile over the past 3 months.
Volatility Over Time: MDXH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 255 | Mike McGarrity | https://mdxhealth.com |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA Fundamentals Summary
MDXH fundamental statistics | |
---|---|
Market cap | €82.41m |
Earnings (TTM) | -€41.04m |
Revenue (TTM) | €58.31m |
1.4x
P/S Ratio-2.0x
P/E RatioIs MDXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MDXH income statement (TTM) | |
---|---|
Revenue | US$63.69m |
Cost of Revenue | US$25.20m |
Gross Profit | US$38.48m |
Other Expenses | US$83.30m |
Earnings | -US$44.82m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.64 |
Gross Margin | 60.42% |
Net Profit Margin | -70.37% |
Debt/Equity Ratio | 201.8% |
How did MDXH perform over the long term?
See historical performance and comparison